Avatar photo

Prof. A.G.(Onno) Holleboom

A.G. (Onno) Holleboom Netherlands

Getting to the heart of nafld/nash – the cvd perspective (part 2)

Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.  
Read More
pannash Webinar -2

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
Read More

Dr. A.G. (Onno) Holleboom (University of Amsterdam UVA, Amsterdam, Netherlands) is a specialist the fields of Endocrinology and Metabolism; vascular medicine. Dr. Holleboom has has worked on research for multiple years in the fields of NASH and NAFLD and continues to be supported by the Amsterdam UMC Fellowship. He is credited with creating an innovative multidisciplinary care model for liver diseases, playing a vital role in the following studies of research:
– innovation of multidisciplinary care
– ANCHOR: Amsterdam NAFLD-NASH cohort study at AMC & VUmc
– LITMUS EU biobank (AMC: Dutch lead center)
– NILE project: prevalence and genetics of NAFLD in the multiethnic Helius cohort
– CRISTINA exercise intervention study in NAFLD
– lipid and liver pathways in rare metabolic diseases, with a focus on defects in lipophagy
– BARNARD: probiotics in mouse models of NAFLD